Preventing Bladder Cancer Recurrence and Progression
Name of the Trial
Why Is This Trial Important?
Researchers are interested in developing effective drug therapies to prevent bladder cancer recurrence after surgery. The use of drugs to prevent cancer or cancer recurrence is called chemoprevention. In this study, two types of drugs are being evaluated to see whether they are effective in preventing bladder cancer recurrence and progression after surgery in patients with a history of smoking.
One of the drugs, Polyphenon E (Mitsui Norin Co. Ltd.), is made from green tea. "Preclinical studies have shown that substances called catechins in green tea extracts are very good at preventing bladder cancer cells from multiplying," said Dr. Belldegrun.
The other drug, erlotinib (Tarceva, OSI Pharmaceuticals), which was recently approved to treat lung cancer, inhibits a protein called epidermal growth factor receptor (EGFR). Approximately 50 percent of bladder tumors show high levels of EGFR, and EGFR expression has been associated with bladder tumor aggressiveness.
"With this study, we hope to find a way to prevent recurrence and, more importantly, to prevent progression of bladder cancer in patients with a history of smoking," Dr. Belldegrun added.
Who Can Join This Trial?
Where Is This Trial Taking Place?
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.